*C U R R I C U L U M  V I T A E*

---

| | |
|---|---|
| *Name* | *Giulio Cesare **Spagnoli*** |
| *Date of birth* | *June 9, 1952, Rome, Italy.* |
| *Address* | *Gemsberg 8, 4051, Basel, Switzerland* |

*Education*

| | |
|---|---|
| *1976 M.D.* | *Universitá di Roma* |
| *1986-1988* | *Research Fellow in Pathology, Dana Farber Cancer Institute,Harvard Medical School, Boston, MA, USA* |
| *1989* | *Stagiaire, Unité d'Immunologie Moleculaire, Institut Pasteur, Paris, France* |
| *1990-1995* | *Senior Research Associate, Zentrum für Lehre und Forschung, University of Basel, Switzerland* |
| *2003* | *Titularprofessor für Experimentelle Chirurgie, Tumorimmunologie, Universität Basel* |
| *2004* | *Deputy Director, Institut für Chirurgische Forschung u. Spitalmanagement, Universität Basel* |

*Prizes and Awards*

*1997 Robert Wenner prize from the Swiss Cancer League (SFR 150,000).*
*2002 Swiss Bridge Foundation award (SFR 250,000).*
*2006 Dora Seif award for Cancer Research of the University of Basel.*

*Major Funding* *Principal Applicant:„Generation of melanoma specific cytotoxic T lymphocyte responses upon stimulation with non replicating immunogens in humans“, Schweizerischer Nationalfonds zur Förderung der wissenschaftlichen Forschung, 1993-2003 (two renewals), SFR 830,000.*

*Principal applicant: “Development of highly predictive anticancer compound “in vitro” screening technologies, Kommission für Teknologie und Innovation, 2009-2012, SFR 730,000.*

*Clinical trials* *Principal Investigator:“Active specific Immunotherapy with recombinant vaccinia viruses expressing melanoma associated antigens and costimulatory molecules, followed by immunization with synthetic melanoma associated antigens“, 1999-2007.*

***Selected original reports (from over 170 peer reviewed articles)***


1. *Certa U, Seiler M, Padovan E, Spagnoli GC. High density oligonucleotide array analysis of interferon-α2a sensitivity and transcriptional response in melanoma cells. Brit J Cancer, 2001, 85: 107-114.*

2. *Bolli M, Kocher T, Adamina M, Guller U, Dalquen P. Haas P. Mirlacher M, Gambazzi F, Harder F, Heberer M, Sauter G, Spagnoli GC. Tissue microarray evaluation of MAGE tumor associated antigens expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. Ann Surg, 2002, 236:785-793.*

3. *Juretic A, Spagnoli GC, Schultz-Thater E, Sarcevic B. Cancer/testis tumour associated antigens: immunohistochemical detection with monoclonal antibodies. The Lancet Oncology, 2003, 4:104-109.*

4. *Zajac P, Oertli D, Marti W, Adamina M, Bolli M, Gueller U, Noppen C, Padovan E, Schultz-Thater E, Heberer M, Spagnoli G Phase I/II clinical trial of a non replicative vaccinia virus expressing multiple HLA-A0201 restricted tumor associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum Gene Ther 2003, 14:1497-1510.*

5. *Ghosh S, Spagnoli GC, Martin I, Ploegert S, Demougin P. Heberer M, Reschner A. Three-dimensional culture of melanoma cells profoundly affects gene expression profile: a high density oligonucleotide array study. J Cell Physiol, 2005; 204:522-531.*

6. *Ghosh S, Rosenthal R, Zajac P, Weber WP, Oertli D, Heberer M, Martin I, Spagnoli GC, Reschner A. Culture of melanoma cells in three-dimensional architectures results in impaired immunorecognition by cytotoxic T lymphocytes specific for Melan-A/MART-1 tumor associated antigen. Ann Surg, 2005; 242:851-857.*

7. *Feder-Mingus C, Ghosh S, Weber WP, Wyler S, Zajac P, Terracciano L, Oertli D, Heberer M, Martin I, Spagnoli GC, Reschner A. Multiple mechanisms underlie defective recognition of melanoma cells cultured in three-dimensional architctures by antigen specific cytotoxic T lymphocytes. Br J Cancer, 2007, 96:1072-1082.*

8. *Feder-Mengus C, Ghosh S, Reschner A, Martin I, Spagnoli GC. New dimensions in tumor immunology: what does 3D culture reveal? Trends Mol Med, 2008, 14:333-340,.*